Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ahmer Farooq

Urology Maywood, IL Doctor of Osteopathy

NPI 1326201666 CMS profile 799671

2160 S 1St Ave, Department Of Urology, Fahey Center Rm 260, Maywood, IL 60153

Open in the dashboard

General payments

$6,818

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,658 paid to institutions, not to them · program year 2025

Through program year 2025, Ahmer Farooq of Maywood, IL is reported in the CMS Open Payments database as having received $6,818 across 75 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $16,658 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 73rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $631 9
2024 General $587 8
2023 General $262 3
2022 General $1,686 14
2021 General $313 6
2020 General $115 1
2019 General $3,225 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmer Farooq
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Ahmer Farooq were reported at $631. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Ahmer Farooq Urology median Middle half National median
2019 $3,225 $480 $147–$1,201 $163
2020 $115 $246 $87–$645 $114
2021 $313 $358 $111–$1,000 $132
2022 $1,686 $476 $143–$1,263 $149
2023 $262 $560 $168–$1,461 $160
2024 $587 $563 $170–$1,464 $164
2025 $631 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $3,668 32 payments
  2. Boston Scientific Corporation $1,339 28 payments
  3. Intuitive Surgical, Inc. $1,316 5 payments
  4. Cook Medical LLC $199 1 payment
  5. PROCEPT BioRobotics Corporation $140 1 payment
  6. 180 Medical, Inc. $61 3 payments
  7. AstraZeneca Pharmaceuticals LP $35 1 payment
  8. Medtronic, Inc. $27 1 payment
  9. Ambu Inc. $16 1 payment
  10. Axonics Modulation Technologies, Inc. $15 1 payment
  11. Other $3 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,445 57 payments
  2. Travel and Lodging $3,311 16 payments
  3. Education $62 2 payments
Products named General payments · program years 2019–2025
  1. TITAN Penile Reconstruction $2,499 19 payments
  2. Da Vinci Surgical System $1,316 5 payments
  3. Titan Men's Health $1,152 12 payments
  4. AMS $429 7 payments
  5. LITHOVUE Scope $217 4 payments
  6. LITHO 150 $199 1 payment
  7. AQUABEAM ROBOTIC SYSTEM $140 1 payment
  8. General - Erectile Dysfunction $133 2 payments
  9. REZUM $115 1 payment
  10. LITHOVUE Pain Management $90 1 payment
  11. Other $395 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,184

Median for Urology: 1,053

Drug cost

$194,438

Median for Urology: $101,464

Branded share of claims

21.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 151 $115,095
Gemtesa Vibegron Brand 22 $20,549
Tamsulosin Hcl Generic 840 $13,431
Mirabegron Er Mirabegron Brand 15 $7,339
Finasteride Generic 374 $5,394
Testosterone Generic 17 $4,658
Methenamine Hippurate Generic 49 $3,803
Solifenacin Succinate Generic 101 $3,378
Potassium Citrate Er Potassium Citrate Brand 26 $2,672
Estradiol Generic 36 $2,144

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$88,478

Medicare's payments for the services billed

Medicare patients

510

Average age 73

Services billed

1,072

89 women, 421 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 37%
Ischemic heart disease 35%
Cancer 30%
Chronic kidney disease 26%
Heart failure 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record